Moderna (MRNA) Cost of Revenue (2020 - 2026)

Moderna has reported Cost of Revenue for 7 years, with the latest figure at $93.0 million in Q2 2026.

• Cost of Revenue for Q2 2026 came in at $93.0 million, down 21.85% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 16.76% YoY), and the FY2025 annual result was $868.0 million, down 40.71% from the prior year.
• Cost of Revenue retreated to $93.0 million in Q2 2026, from $955.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.2 billion in Q3 2023 and troughed at $90.0 million in Q1 2025.
• A 5-year average of $665.1 million and a median of $622.5 million in 2023 frame the typical range for Cost of Revenue.
• The widest annual swing landed in 2024, when Cost of Revenue tumbled 87.88%; it then jumped 961.11% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $400.0 million in 2022, then jumped by 132.25% to $929.0 million in 2023, then dropped by 20.45% to $739.0 million in 2024, then plunged by 38.84% to $452.0 million in 2025, then sank by 79.42% to $93.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $93.0 million in Q2 2026, $955.0 million in Q1 2026, and $452.0 million in Q4 2025.